Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Insilico Medicine lands up to $888M deal with French firm Servier to develop cancer drugs using its AI platform.

flag Insilico Medicine has secured an up to $888 million deal with French drugmaker Servier to develop cancer treatments using its AI platform, Pharma.AI, just days after its Hong Kong IPO. flag The agreement includes $32 million in upfront and near-term payments, with additional funds based on milestones. flag Insilico will use generative AI to design new drug molecules, while Servier handles R&D, clinical testing, and commercialization. flag The company claims its AI can cut drug development time from 4.5 years to 12–18 months. flag This deal adds to Insilico’s growing list of AI partnerships, including with Eli Lilly, Fosun Pharma, and Sanofi, with 61 collaborations reported in early 2025. flag Despite a slight dip in Insilico’s Hong Kong shares, the healthcare sector there saw increased listings due to supportive policies.

5 Articles